Newcourt (NASDAQ:NCAC) has closed its combination with psychedelic medicine company Psyence (CSE:PSYG) and will begin trading on The Nasdaq under the new ticker symbol ticker symbol “PBM” on January 26.
Shareholders previously approved the combination during a special meeting held on January 18.
In connection with last week’s vote, shareholders opted to redeem 929,727 shares at a redemption price of approximately $11.51 per share, removing about $10.7 million from Newcourt’s trust and leaving it with 183,294 public shares outstanding and about $2.1 million in trust.
In connection with the combination, Psyence Biomed entered into a securities purchase agreement under which it will raise up to $10 million in funding through the issuance of up to four senior secured convertible notes with a US-based investment firm. The combined company intends to use the note financing to further its clinical trials conducted in Australia.
Psyence Biomed has partnered with the Australian-based research organization iNGENu to conduct its clinical trial in palliative care. Upon successful completion of the study, the combined company plans to conduct a multinational Phase III study.
The SPAC announced its deal with Psyence in January 2023. The Canada-listed company is developing psychedelic drug candidates to potentially treat patients in palliative care and those with severe psychological conditions.
Psyence Biomedical plans to use the funds from the deal to expedite its clinical trials and expand its market presence.
ADVISORS
- Bayline Capital Partners Inc. is acting as capital markets advisor to Psyence.
- WeirFoulds LLP is acting as Canadian legal advisor to Psyence.
- Morgan, Lewis & Bockius LLP is acting as U.S. legal advisor to Psyence.
- McDermott Will & Emery LLP is acting as U.S. legal advisor to Newcourt.
YHN Acquisition I Limited announced the pricing of its $60 million IPO and its units are expected to begin trading on the Nasdaq under the symbol “YHNAU”, Wednesday, September 18, 2024. The new SPAC’s search will not be limited to a particular industry or geographic location, but the sponsors intend to target companies with a...
Chenghe II (NYSE:CHEB) has entered into a definitive agreement to combine with the Polibeli Group at a $3.6 billion equity value. Jakarta-based Polibeli operates an online and app-based wholesale marketplace for small businesses on Indonesia’s Java island. The combined company is expected to trade on the NYSE once the deal is completed. Transaction Overview Chenghe...
Horizon Space I (NASDAQ:HSPO) has entered into a definitive agreement to combine with brand marketing firm Squirrel Enlivened for $200 million in equity consideration. Shenzhen, China-based Squirrel Enlivened serves as a video and print ad agency for Asian clients of a variety of sizes. The combined company is expected to trade on the Nasdaq once...
At the SPAC of Dawn SPACs celebrated the beginning of the Fed meeting today with two new deal announcements. Both transactions are by Asia-based teams, but represent seemingly very different processes. Horizon Space I (NASDAQ:HSPO) has been working on its combination with Squirrel Enlivened since at least last October, when it signed an letter of...
Many things go into an M&A transaction negotiation, but one of the most common points at issue in SPAC deals is the fate of the sponsor’s promote. While the two sides might wrangle back and forth on the target’s valuation and potential earnout consideration, it is also common for the sponsor to agree to concessions...